Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (61-70 of 146) with videos related to

Pageof 15
Sort By:
BMC Cancer|October 5, 2018
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)Motoko Tachihara, Shunichi Negoro, Takako Inoue, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
BMC Cancer|November 18, 2015
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutationsKatsuhiro Masago, Shiro Fujita, Miho Muraki, et al.
BMC Cancer|January 3, 2018
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancerToshihiko Kaneda, Hiroshige Yoshioka, Motohiro Tamiya, et al.
Therapeutic Drug Monitoring|July 27, 2018
An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug MonitoringKei Irie, Akira Okada, Yuta Yamasaki, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 14, 2018
Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapyKei Irie, Akira Okada, Yoshio Masuda, et al.
Japanese Journal of Clinical Oncology|November 8, 2011
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patientsAkito Hata, Nobuyuki Katakami, Kei Kunimasa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2015
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKIAkito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Oncotarget|January 27, 2018
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 3, 2010
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancerAkito Hata, Hiroshige Yoshioka, Shiro Fujita, et al.
Pageof 15

Showing results (61-70 of 146) with videos related to

Sort By:
Pageof 15
BMC Cancer|October 5, 2018
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)Motoko Tachihara, Shunichi Negoro, Takako Inoue, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
BMC Cancer|November 18, 2015
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutationsKatsuhiro Masago, Shiro Fujita, Miho Muraki, et al.
BMC Cancer|January 3, 2018
Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancerToshihiko Kaneda, Hiroshige Yoshioka, Motohiro Tamiya, et al.
Therapeutic Drug Monitoring|July 27, 2018
An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug MonitoringKei Irie, Akira Okada, Yuta Yamasaki, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 14, 2018
Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapyKei Irie, Akira Okada, Yoshio Masuda, et al.
Japanese Journal of Clinical Oncology|November 8, 2011
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patientsAkito Hata, Nobuyuki Katakami, Kei Kunimasa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2015
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKIAkito Hata, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Oncotarget|January 27, 2018
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Shigeki Nanjo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 3, 2010
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancerAkito Hata, Hiroshige Yoshioka, Shiro Fujita, et al.
Pageof 15